Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2
Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”.
Posts Tagged ‘NASDAQ:REGN’
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Regeneron Pharmaceuticals, Inc.
10 Best Innovative Healthcare Stocks to Buy Now
The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc.
10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds
On June 9, Reuters reported that Philips' Future Health Index survey concluded that artificial intelligence improved clinical accuracy and increased patient capacity.
10 Best Non-Tech Stocks to Buy According to Analysts
On June 24, Tom Lee, Head of Research at Fundstrat Global Advisors, appeared on CNBC to talk about how the semiconductor selloff is a buying opportunity, earnings growth is supporting...
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on r/investing_discussion by Variant_Invest.
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc.
10 Best Healthcare Stocks to Buy with Highest Upside Potential
On June 1, Tom Lee, Fundstrat managing partner and head of research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, the...
10 Best Debt-Free S&P 500 Stocks to Buy Now
Debt-free S&P 500 stocks are getting more attention as investors look for companies that can keep operating without depending heavily on borrowing.
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event
Regeneron Pharmaceuticals, Inc.
10 Cheap NASDAQ Stocks to Buy Right Now
On April 28, Gabelli's John Belton joined CNBC's 'Closing Bell Overtime' to analyze the market environment heading into earnings season.
12 Best Medical Stocks to Invest In According to Billionaires
On May 20, Nancy Tengler of Laffer Tengler Investments appeared on CNBC to talk about the market reaction to economic conditions and how a likely pullback represents a good buying...
Don’t Ignore This Market Rotation: Jim Cramer’s Views on Intel, Vertiv, TSMC, and More
In this article, we will look at the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation.
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2026 Earnings Call Transcript April 29, 2026Regeneron Pharmaceuticals, Inc. beats earnings expectations.
TD Cowen Lifts PT on Regeneron Pharmaceuticals (REGN) Ahead of Fiscal Q1 Results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best stem cell therapy stocks to buy. TD Cowen lifted the price target on Regeneron Pharmaceuticals, Inc.
8 Best Stem Cell Therapy Stocks to Buy
On April 23, Bankim Chadha, chief global strategist at Deutsche Bank, appeared on CNBC's ‘Money Movers’ to talk about uncertainty in the markets and what to expect with the...
Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most undervalued biotech stocks to buy right now. Regeneron Pharmaceuticals, Inc.
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Jim Cramer Weighed In on the Tech Market Divide and 11 Stocks to Watch Now
In this article, we will look at the stocks Jim Cramer discussed alongside the tech market divide.
Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks
In this article, we will discuss: Jim Cramer's Hottest GLP-1 and Weight Loss Stock Picks.
8 Best Debt Free Stocks to Buy Right Now
The market environment has become more complicated following the recent energy shock tied to the Iran conflict, with inflation concerns resurfacing just as expectations for rate...
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack.
Jim Cramer Looked at These 11 Stocks Recently
This very morning, Larry sent me an email saying, hey, you know what? It's time for Bitcoin to blast off.
Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now.
11 Best Value Stocks to Buy Now
On February 7, Richard Bernstein, the CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the current state of the equity markets and his firm's macro-...
Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets...
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under...
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov.
Regeneron (REGN) Draws Higher Target From TD Cowen
During the Q4 2025 earnings call, CEO Leonard Schleifer said Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered steady revenue growth.
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026Regeneron Pharmaceuticals, Inc. beats earnings expectations.
13 Companies that Just Started Paying Dividends
The latest figures from S&P Dow Jones Indices show dividend growth didn’t stall in 2025, but it clearly slowed.
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)
TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock.
20 Most Profitable Stocks of the Last 20 Years
Investing in the stock market could be both advantageous and difficult, especially for those seeking companies with robust long-term development and profitability.
Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its fourth-quarter 2025 investor letter for the “Baird Chautauqua...
Should You Be Excited for Regeneron (REGN)?
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)
On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc.
10 Best Debt Free Dividend Stocks to Buy Now
Debt was once avoided by most S&P 500 technology companies. That mindset is changing.
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating
On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on Regeneron Pharmaceuticals, Inc.
14 Best US Stocks to Buy for Long Term
Investors around the world focus on long-term strategies, and for that, they are looking beyond traditional investment ideas.
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov.
Hedge Fund Resource Center
